Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes.
Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes.
复制标题
DOI：
10.1016/j.jconrel.2004.02.029
复制
发表时间：
2004-06
期刊：
影响因子：
--
通讯作者：
Kerstin Tabatt;C. Kneuer;M. Sameti;C. Olbrich;R. Müller;C. Lehr;U. Bakowsky
中科院分区：
文献类型：
--
作者：
Kerstin Tabatt;C. Kneuer;M. Sameti;C. Olbrich;R. Müller;C. Lehr;U. Bakowsky
用于基因转移的阳离子固体脂质纳米颗粒 (SLN) 使用与脂质体转染剂相同的阳离子脂质配制。为了研究 SLN 和脂质体之间结构和性能的差异和相似性，对 SLN 制剂 (S1)、不含基质脂质的对应制剂 (L1)、市售脂质体制剂 (DLTR)（均基于阳离子脂质 DOTAP）以及另外含有辅助脂质二油酰磷脂酰乙醇胺 (DOPE) (Escort™) 的脂质体制剂进行了比较。光子相关光谱 (PCS) 显示 SLN 的直径小于相应的脂质体 (88 nm vs. 148 nm)，原子力显微镜 (AFM) 支持预期的结构差异。脱氧核糖核酸 (DNA) 结合仅略有不同。令人惊讶的是，所有基于 DOTAP 的制剂（S1、L1、DLTR）之间的报告基因表达相当，仅被含有 DOPE 的脂质体（Escort™）超越。总之，对于体外转染性能而言，阳离子脂质成分似乎比其所排列的胶体结构类型更占主导地位。因此，阳离子 SLN 通过一种具有有利且独特的技术特性的技术扩展了高效非病毒转染剂的范围。关于脂质体制剂中阳离子脂质的积累的知识应该有助于进一步的 SLN 优化。
Cationic solid lipid nanoparticles (SLN) for gene transfer are formulated using the same cationic lipids as for liposomal transfection agents. To investigate the differences and similarities in structure and performance between SLN and liposomes, a SLN preparation (S1), its counterpart formulation without matrix lipid (L1), a commercially available liposomal preparation (DLTR) — all based on the cationic lipid DOTAP—and a liposomal formulation that additionally contained the helper lipid dioleoylphosphatidylethanolamine (DOPE) (Escort™) were compared. Photon correlation spectroscopy (PCS) showed that the SLN were smaller in diameter than the corresponding liposomes (88 vs. 148 nm) and atomic force microscopy (AFM) supported the expected structural differences. Desoxy ribonuclein acid (DNA) binding differed only marginally. Surprisingly, reporter gene expression was comparable between all DOTAP based formulations (S1, L1, DLTR), surpassed only by the DOPE containing liposomes (Escort™). In conclusion, cationic lipid composition seems to be more dominant for in vitro transfection performance than the kind of colloidal structure it is arranged in. Hence, cationic SLN extend the range of highly potent non-viral transfection agents by one with favourable and distinct technological properties. Further SLN optimisation should be facilitated by the accumulated knowledge about cationic lipids in liposomal formulations.